Welcome to our dedicated page for Icon Plc news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on Icon Plc stock.
ICON plc (ICLR) is a leading global provider of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. Headquartered in Ireland, ICON specializes in the strategic development, management, and analysis of clinical programs that support clinical development from compound selection to phase I-IV clinical studies.
Operating in a highly fragmented industry, ICON is among a select group of organizations with the capability and expertise to conduct clinical trials and development projects on both a local and global scale. The company's core services are versatile, offering both standalone and integrated full-service solutions to meet diverse client needs. This operational flexibility ensures that ICON can tailor its services to individual project requirements.
ICON's array of services includes end-to-end pharmacovigilance, which covers post-marketing surveillance activities. The company also provides ancillary services, such as laboratory and imaging capabilities, enhancing its comprehensive approach to drug development and clinical research.
This robust service offering positions ICON as a pivotal partner for firms aiming to bring their medical innovations to market. Recent achievements and ongoing projects underscore ICON's commitment to excellence and innovation in clinical research. The company's financial health remains strong, supported by strategic partnerships and a global client base.
Stay updated on ICON plc's latest developments, performance updates, and industry news to understand the significant role this organization plays in advancing healthcare solutions worldwide.
ICON plc (ICLR) has announced its financial guidance for the year ending December 31, 2023. Expected revenue ranges from
ICON plc (NASDAQ: ICLR), a leader in healthcare intelligence and clinical research, announced that CEO Dr. Steve Cutler will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 5:15 PM PST/8:15 PM EST. The conference will showcase key insights into ICON's operations and strategy. Changes to the event will be updated on the Investor Relations section of their website under 'Events'. With approximately 41,150 employees across 113 locations in 53 countries, ICON is committed to advancing clinical research and improving patient lives.
On November 28, 2022, BetterInvesting Magazine announced Icon PLC (NYSE: ICLR) as its "Stock to Study" and Williams-Sonoma Inc. (NYSE: WSM) as its "Undervalued Stock" for the January-February 2023 issue. The initiative is aimed at enhancing investors' financial literacy and empowering informed investment decisions. BetterInvesting encourages potential investors to conduct thorough reviews using their online tools. The recommendations serve purely educational purposes and do not constitute endorsements for purchase.
ICON plc (NASDAQ: ICLR), a global leader in healthcare intelligence and clinical research, announced that CFO Brendan Brennan will present at the 2022 Evercore ISI HealthCONx Conference on November 30, 2022, at 08:00 am EST. The presentation will be available via live webcast. For updates and links to the webcast, visit the Investor section of ICON's website under 'Events'. As of September 30, 2022, ICON employed around 41,150 people across 113 locations in 53 countries, enhancing clinical research and patient care.
ICON plc (NASDAQ: ICLR) reported third quarter 2022 results showcasing strong financial performance. Net business wins reached $2,351 million, with a book-to-bill ratio of 1.21. Revenue for Q3 was $1,942.4 million, up 3.9% year-on-year. Year-to-date revenue hit $5,779.4 million, reflecting a 60.6% increase. Adjusted EBITDA stood at $379.6 million, representing 19.5% of revenue. Adjusted net income was $247.2 million, leading to $3.00$7,690 - $7,810 million.
ICON plc (NASDAQ: ICLR) has been selected by the US Biomedical Advanced Research and Development Authority (BARDA) to conduct a clinical trial for the AV7909 anthrax vaccine. Funded by BARDA, this trial aims to evaluate the immune response of healthy adults to the next-generation vaccine, with activities including project management and clinical operations. ICON has significant experience in vaccine studies, participating in over 160 trials in the past five years. The trial will start in early 2023, addressing the potential threat of anthrax exposure.
ICON plc (NASDAQ: ICLR) will release its Q3 2022 financial results on November 2, 2022, post market close. A conference call will follow on November 3, 2022, at 8:00 AM ET to discuss the results. As of June 30, 2022, ICON employed approximately 40,500 staff across 119 locations in 53 countries. The firm emphasizes its role in advancing clinical research and patient care, but noted that forward-looking statements are subject to risks that could affect actual results. Further updates will be provided on the Investor Relations section of the ICON website.
ICON plc (NASDAQ: ICLR), a global leader in healthcare intelligence and clinical research, announced that CFO Brendan Brennan will present at the 2022 Wells Fargo Healthcare Conference on September 7, 2022, at 10:25 AM EDT. The presentation will be accessible via a live webcast, with any updates available on their investor website under the 'Events' section. ICON, headquartered in Dublin, Ireland, employs approximately 40,500 individuals across 119 locations in 53 countries as of June 30, 2022.
FAQ
What is the current stock price of Icon Plc (ICLR)?
What is the market cap of Icon Plc (ICLR)?
What services does ICON plc provide?
Where is ICON plc headquartered?
What is ICON's role in pharmaceutical development?
Does ICON offer standalone and integrated services?
What is pharmacovigilance, and does ICON provide it?
What industries does ICON serve?
What makes ICON a leader in its industry?
How can I stay updated on ICON's latest news and developments?
What are some of ICON's ancillary services?
What type of clients does ICON work with?
